[18F] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
[18F] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
复制标题
DOI：
10.1200/jco.2005.01.7079
复制
发表时间：
2005-12-01
影响因子：
45.3
通讯作者：
Eary, JF
中科院分区：
文献类型：
--
作者：
Hawkins, DS;Schuetze, SM;Eary, JF
目的：对新辅助化疗的反应是影响Ewing肉瘤家族肿瘤预后的重要因素。[F-18]氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）是一种无创成像方式，可以准确预测几种恶性肿瘤的组织病理反应。为了确定FDG PET反应对ESFTs无进展生存期（PFS）的预后价值，我们回顾了华盛顿大学医学中心的经验。患者与方法对36例ESFTs患者进行FDG PET评价。所有患者均接受新辅助和辅助化疗。通过手术切除肿瘤的组织病理学评估，分析化疗前（SUV1）和化疗后（SUV2）的FDG PET标准摄取值并将其与化疗反应相关联。34例患者同时患有SUV1和SUV2。结果SUV1、SUV2的均值为7.9（范围2.3 ~ 32.8），SUV2与SUV1之比为2.1（范围0 ~ 4.3），SUV1与SUV1之比为0.36（范围0.00 ~ 1.00）。FDG PET良好反应定义为SUV2小于2.5或SUV2 2:1 = 2.5，所有患者P = 0.01；80%的SUV2 < 2.5 v， 33%的SUV2 >= 2.5, P = 0.036，局限于诊断患者)。SUV2:1
Purpose Response to neoadjuvant chemotherapy is a significant prognostic factor for the Ewing sarcoma family of tumors (ESFTs). [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET) is a noninvasive imaging modality that accurately predicts histopathologic response in several malignancies. To determine the prognostic value of FDG PET response for progression-free survival (PFS) in ESFTs, we reviewed the University of Washington Medical Center experience.Patients and Methods Thirty-six patients with ESFTs were evaluated by FDG PET. All patients received neoadjuvant and adjuvant chemotherapy. FDG PET standard uptake values before (SUV1) and after (SUV2) chemotherapy were analyzed and correlated with chemotherapy response, as assessed by histopathology in surgically excised tumors. Thirty-four patients had both SUV1 and SUV2.Results The mean SUV1, SUV2, and ratio of SUV2 to SUV1 (SUV2:1) were 7.9 (range, 2.3 to 32.8), 2.1 (range, 0 to 4.3), and 0.36 (range, 0.00 to 1.00), respectively. Good FDG PET response was defined as SUV2 less than 2.5 or SUV2:1 = 2.5, P = .01 for all patients; 80% for SUV2 < 2.5 v 33% for SUV2 >= 2.5, P = .036 for localized at diagnosis patients). SUV2:1